Medexus Pharmaceuticals

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company based in Seattle, Washington, dedicated to the discovery and development of innovative therapeutics for oncology and hematology. The company markets IXINITY, a coagulation factor IX treatment for hemophilia B, which is used for managing bleeding episodes. Its lead clinical candidate, APVO436, is currently undergoing Phase 1/1b trials for acute myeloid leukemia and high-grade myelodysplastic syndrome. Aptevo also has several preclinical candidates, including ALG.APV-527 and APVO603, which are designed using the ADAPTIR platform technology, aimed at enhancing immune responses against cancer. The company collaborates with Alligator Bioscience AB for the development of ALG.APV-527. Founded in 2016, Aptevo Therapeutics focuses on leveraging its proprietary technologies to improve patient outcomes in cancer treatment.

Medexus Pharmaceuticals Inc. is a specialty pharmaceutical company operating in Canada and the United States, dedicated to developing and commercializing treatments for rare and auto-immune diseases. The company's primary products include Rasuvo and Metoject, which are formulations of methotrexate for rheumatoid arthritis and other auto-immune conditions. Additionally, Medexus offers IXINITY, a therapeutic for Hemophilia B, and Rupall, indicated for various allergic conditions. The company's portfolio also features Cuvposa for sialorrhea, Gliolan for brain tumor visualization, and Treosulfan, used in stem cell transplantation preparation. Medexus Pharmaceuticals, based in Verdun, Canada, previously operated as Pediapharm Inc. and has since expanded its focus to include a range of therapeutic areas such as rheumatology, oncology, hematology, allergy, and pediatrics.

Medac Pharma specializes in the development and treatment of cancer, autoimmune diseases, and urological diseases.